Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity

This article originally appeared here.
Share this content:
Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity
Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity

TUESDAY, Aug. 30, 2016 (HealthDay News) -- For acute major bleeding within 18 hours after factor Xa inhibitor administration, a bolus and infusion of andexanet alfa (andexanet) reduces factor Xa activity, according to a study published online Aug. 30 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 27 to 31 in Rome.

Stuart J. Connolly, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a multicenter trial involving 67 patients with acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients all received a bolus of andexanet followed by a two-hour infusion.

The researchers found that among patients receiving rivaroxaban and apixaban, the median anti-factor Xa activity decreased by 89 and 93 percent, respectively, from baseline after the bolus administration. During the two-hour infusion these levels remained similar. There was a relative decrease from baseline of 39 and 30 percent in the measure of anti-factor Xa activity at four hours after the end of the infusion for patients receiving rivaroxaban and apixaban, respectively. Clinical hemostasis was excellent or good at 12 hours after andexanet infusion in 79 percent of patients in the efficacy analysis.

"An initial bolus and subsequent two-hour infusion of andexanet substantially reduced anti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitors, with effective hemostasis occurring in 79 percent," the authors write.

The study was funded by Portola Pharmaceuticals, the developer of andexanet alfa.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »